Liver failure in a child receiving highly active antiretroviral therapy and voriconazole

Clinical Infectious Diseases

Volumn 37, Issue 6, 2003, Pages 828-830

  Scherpbier, Henriette J ^a   Hilhorst, Michaela I ^a   Kuijpers, Taco W ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AMPRENAVIR; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; FLUCYTOSINE; LOPINAVIR; NEVIRAPINE; RANITIDINE; RITONAVIR; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; CHILD; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG TOLERABILITY; FAILURE TO THRIVE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INTESTINE ENDOSCOPY; LIVER FAILURE; PRIORITY JOURNAL; SIDE EFFECT; THRUSH; VERTICAL TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DISEASE TRANSMISSION, VERTICAL; FATAL OUTCOME; FEMALE; HUMANS; LIVER FAILURE; PYRIMIDINES; TRIAZOLES;

EID: 0141564729     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376985     Document Type: Article

References (10)

1. Patterson B, Roffey S, Jezequel S, Jones B. UK-109496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man [abstract F79]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:126.
2. Frederiks AM, van Buuren S, Bugmeijer RJ, et al. Continuing positive secular growth change in the Netherlands 1955-1997. Pediatr Res 2000; 47:316-23.
3. Krilov LR, Kaplan MH, Frogel M, Rubin LG. Fatal adenovirus disease and human immunodeficienmcy virus infection. Pediatr Infect Dis J 1990; 9:434-6.
4. Melvin AJ, Lewis PF, Mohan KM, Naugler WS, Frenkel LM. Efficacy of a strategy for antiretroviral management in human immunodeficiency virus-infected children. Arch Pediatr Adolesc Med 2002; 156:568-73.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
6. Vfend tablets (voriconazole) [product information]. New York: Pfizer, 2003. Available at: http://www.pfizer.com/do/medicines/mn_vfend.html. Last accessed: 18 August 2003.
7. Walsh TJ, Pappas PP, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for emperical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
8. Denning DW, Ribaud P, Milpied N, et al. Efficacy and savety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
9. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46:2546-53.
10. Walsh, TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-48.